mercredi 25 juin 2014

Sony not so bad anymore for healthcare in China

Sony not so bad anymore for healthcare in China

In 2000, Beijing had suspended the sale of all the games consoles in the country because of their supposed negative effects on «the mental healthcare” of the young Chinese users. From now on, after Microsoft with its console Xbox One, it's the turn of Sony to confirm soon the availability of its last one Playstation 4 in China.

Sony in China


The Japanese giant of the electronics established in Shanghai two joint ventures which will allow it to introduce its consoles into the Middle Kingdom. It is «A very promising market” for Sony, in a country which counts approximately 500 million players. Dominated by the programs on the Internet and the applications of smartphones, the sector of the video game generated in China income about 7,2 billion euros in 2013, increasing by 38 % over one year.
If the import of foreign consoles in China remains forbidden, Beijing gave its approval in January to the sale onto the Chinese market of games consoles provided that they are made in the free zone of Shanghai inaugurated last September.
Sony joined to Oriental Pearl, firm of leisure activities and entertainment, to set up two joint ventures based in the Shanghainese territory, the one dedicated to the production of consoles and the other one to that of the video games and the relative services, according to a common statement of both groups. Sony will possess 49 % of the parts of one of the entities, and 70 % of the capital of second.
According to the specialists of the sector, these PS4 “made in Mocked” cannot read the games of the other regions of the world. And they will be subjected to a censorship increased to respect at best the drastic standards of the local authorities. The joint ventures of Sony have already warned that the games will be " of quality and healthy " to answer the requirement formulated by the Chinese regulators which do not want contents considered violent, obscene or politically sensitive, risky for healthcare in China.